Bioamber Inc (NYSE:BIOA)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $0.19 and last traded at $0.19, with a volume of 7037684 shares trading hands. The stock had previously closed at $0.38.
Several research firms recently issued reports on BIOA. ValuEngine cut Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Cowen reaffirmed a “hold” rating and issued a $1.00 price objective on shares of Bioamber in a research report on Friday, November 10th. Zacks Investment Research raised Bioamber from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Bioamber in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the stock. Bioamber presently has a consensus rating of “Hold” and an average price target of $6.50.
The firm has a market cap of $9.90, a PE ratio of -0.23 and a beta of 2.52. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24.
A number of hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Bioamber by 1.9% in the 2nd quarter. FMR LLC now owns 1,360,000 shares of the biotechnology company’s stock valued at $3,495,000 after acquiring an additional 25,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Bioamber by 9.9% during the 2nd quarter. Vanguard Group Inc. now owns 303,360 shares of the biotechnology company’s stock valued at $780,000 after buying an additional 27,278 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Bioamber by 336.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 54,106 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 41,701 shares during the last quarter. Finally, Robecosam AG raised its stake in Bioamber by 82.9% during the 3rd quarter. Robecosam AG now owns 1,478,000 shares of the biotechnology company’s stock valued at $741,000 after buying an additional 670,000 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Bioamber (BIOA) Reaches New 12-Month Low at $0.19” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.com-unik.info/2018/02/08/bioamber-bioa-reaches-new-12-month-low-at-0-19.html.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with MarketBeat.com's FREE daily email newsletter.